SYK vs. ABT, ISRG, BSX, MDT, BDX, EW, DXCM, IDXX, RMD, and STE
Should you be buying Stryker stock or one of its competitors? The main competitors of Stryker include Abbott Laboratories (ABT), Intuitive Surgical (ISRG), Boston Scientific (BSX), Medtronic (MDT), Becton, Dickinson and Company (BDX), Edwards Lifesciences (EW), DexCom (DXCM), IDEXX Laboratories (IDXX), ResMed (RMD), and STERIS (STE). These companies are all part of the "health care equipment" industry.
Stryker (NYSE:SYK) and Abbott Laboratories (NYSE:ABT) are both large-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, valuation, media sentiment, risk, analyst recommendations, community ranking, earnings, dividends and profitability.
Stryker pays an annual dividend of $3.20 per share and has a dividend yield of 0.9%. Abbott Laboratories pays an annual dividend of $2.20 per share and has a dividend yield of 2.2%. Stryker pays out 36.5% of its earnings in the form of a dividend. Abbott Laboratories pays out 68.5% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years.
Stryker has a net margin of 16.03% compared to Abbott Laboratories' net margin of 13.96%. Stryker's return on equity of 23.05% beat Abbott Laboratories' return on equity.
Abbott Laboratories received 30 more outperform votes than Stryker when rated by MarketBeat users. Likewise, 69.64% of users gave Abbott Laboratories an outperform vote while only 64.49% of users gave Stryker an outperform vote.
Abbott Laboratories has higher revenue and earnings than Stryker. Abbott Laboratories is trading at a lower price-to-earnings ratio than Stryker, indicating that it is currently the more affordable of the two stocks.
Stryker currently has a consensus price target of $370.58, suggesting a potential upside of 8.65%. Abbott Laboratories has a consensus price target of $120.64, suggesting a potential upside of 18.05%. Given Abbott Laboratories' higher probable upside, analysts plainly believe Abbott Laboratories is more favorable than Stryker.
In the previous week, Abbott Laboratories had 4 more articles in the media than Stryker. MarketBeat recorded 22 mentions for Abbott Laboratories and 18 mentions for Stryker. Stryker's average media sentiment score of 1.09 beat Abbott Laboratories' score of 0.54 indicating that Stryker is being referred to more favorably in the media.
Stryker has a beta of 0.91, suggesting that its stock price is 9% less volatile than the S&P 500. Comparatively, Abbott Laboratories has a beta of 0.76, suggesting that its stock price is 24% less volatile than the S&P 500.
77.1% of Stryker shares are held by institutional investors. Comparatively, 75.2% of Abbott Laboratories shares are held by institutional investors. 5.9% of Stryker shares are held by company insiders. Comparatively, 1.1% of Abbott Laboratories shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Summary
Stryker beats Abbott Laboratories on 13 of the 20 factors compared between the two stocks.
Get Stryker News Delivered to You Automatically
Sign up to receive the latest news and ratings for SYK and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding SYK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
